Merck's Keytruda takes home adjuvant win in melanoma, escalating early-line fight with Bristol Myers
With immune checkpoint inhibitors quickly emerging as standard of care across a broad range of advanced cancers, the biggest drugmakers in the race are making …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
